Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cgc-11047. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SAT1 | P21673 | 3/20 | 0.44 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cgc-11047 SCHEMBL2359065 | 1.00 | KDM1A (1.00) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Cgc-11047 SCHEMBL427906 | 1.00 | KDM1A (1.00) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Cgc-11047 SCHEMBL2360444 | 0.97 | KDM1A (1.00) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Cgc-11047 SCHEMBL2359734 | 0.97 | KDM1A (1.00) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Cgc-11047 SCHEMBL2359741 | 0.97 | KDM1A (1.00) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Cgc-11047 SCHEMBL8640381 | 0.95 | KDM1A (0.95) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Cgc-11047 SCHEMBL8640375 | 0.95 | KDM1A (0.95) | KDM1ACYP2C19MEN1GLAKMT2A | |
| SCHEMBL12085577 | 0.92 | KDM1A (0.95) | KDM1ACYP2C19MEN1GLAKMT2A | |
| SCHEMBL13097481 | 0.92 | KDM1A (0.95) | KDM1ACYP2C19MEN1GLAKMT2A | |
| Hydrochloric Acid SCHEMBL8639045 | 0.91 | KDM1A (0.83) | KDM1ACYP2C19MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937235-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | Pathologica, LLC. (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007035957-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-20050159493-A1 | Methods for modulating macrophage proliferation using polyamine analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-07-21 | — | — | US | claimed |
| JP-2001520990-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-1027040-A2 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS | The Regents of the University of California (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021542-A2 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-05-06 | — | — | WO | claimed |
| EP-3228310-A1 | METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT | Pathologica LLC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2121586-B1 | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS | PATHOLOGICA LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1937235-B1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20130102556-A1 | Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120219970-A1 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION IN OCULAR DISEASE USING POLYAMINE ANALOGS | PATHOLOGICA LLC (US) | 2012-08-30 | — | — | US | disclosed |
| US-8198334-B2 | Vitreoretinopathy, diabetic retinopathy, nonexudative age related macular degeneration; small molecule amines | PATHOLOGICA LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120022166-A1 | Methods for Modulating Macrophage Proliferation Using Polyamine Analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-01-26 | — | — | US | disclosed |
| EP-0934249-A1 | CONFORMATIONALLY RESTRICTED POLYAMINES AND THEIR USE AS ANTINEOPLASTIC AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5889061-A | ANTICANCER, ANTITUMOR AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0686143-B1 | UNSATURATE AMINO COMPOUNDS FOR USE AS ANTICANCER AND ANTIPROTOZOIC AGENT | CIBA GEIGY AG (CH) | 1998-08-12 | — | — | EP | disclosed |
| WO-1998017624-A1 | CONFORMATIONALLY RESTRICTED POLYAMINES AND THEIR USE AS ANTINEOPLASTIC AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-04-30 | — | — | WO | disclosed |
| US-5627215-A | Unsaturate amino compounds for use as anticancer and antiprotozoic agent | CIBA-GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0686143-A1 | UNSATURATE AMINO COMPOUNDS FOR USE AS ANTICANCER AND ANTIPROTOZOIC AGENT | Novartis AG (CH) | 1995-12-13 | — | — | EP | disclosed |
| WO-1995018091-A1 | UNSATURATE AMINO COMPOUNDS FOR USE AS ANTICANCER AND ANTIPROTOZOIC AGENT | CIBA-GEIGY AG (CH) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102556-A1 | Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy | DNMT1, DNMT3L, TET1 | GLA 2599/4885KDM1A 38/4885CYP2C19 3651/4885 |
| US-20120022166-A1 | Methods for Modulating Macrophage Proliferation Using Polyamine Analogs | ARG1, MKI67, CSF1R | GLA 833/4885KDM1A 259/4885CYP2C19 4826/4885 |
| US-20050159493-A1 | Methods for modulating macrophage proliferation using polyamine analogs | ARG1, MKI67, CSF1R | GLA 833/4885KDM1A 259/4885CYP2C19 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.